Search

Acrizanib

Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).

ALM201

ALM201 is an anti-angiogenic synthetic peptide identified from the endogenous human protein, FKBPL. It is being investigated in the treatment of various cancers.[A254556]

TP-252

TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.[A259956]

ABBV-011

ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.

SGS518

SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

ACE393

ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

Zamubafusp alfa

Zamubafusp alfa is an immunoglobulin-peptide fusion protein.[L55038] It consists of a humanized IgG1 and p5R which is a pan-amyloid reactive peptide.[L55038]

7,8-dihydrobiopterin

7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.

Alicaforsen

Tin protoporphyrin IX